Cardiology

LIST OF CLINICAL TRIALS BY THERAPEUTIC AREA

  • CARDIOLOGY

  • ENDOCRINOLOGY

  • MULTIPLE ESCLEROSIS

  • RARE DISEASES

CARDIOLOGY

Basic Research:

Study: Evidence for Linkage between Essential Hypertension and a Putative Locus on Human Chromosome 17. Hypertension. 1999;34:4-7

    1. Role: researcher and first author
    2. Status: published

Study: Identification of a polymorphic glutamic acid stretch in the 2-β adrenergic receptor and lack of association with essential hypertension. Am J Hypert 1999: 12(9 Pt 1): 853-7

      1. Role; researcher and author
      2. Status: published

Study: Mitochondrial DNA mutations in patients with orthostatic hypotension. American Journal of Medical Genetics 1999, 86:2, 145-5.

        1. Role: researcher and author
        2. Status: published

Drug: Levosimendan

Indication: Heart failure

Manufacturer: Abbott

Study: Levosimendan treatment for acutely decompensated heart failure is as effective for Chagas disease patients as for patients with other etiologies. Critical Care 2003, 7(Suppl 3):P23

  1. Role: protocol development, site selection and author
  2. Phase: 3b
  3. Status: published

Study: Levosimendan in Decompensated Heart Failure Patients: Efficacy in a Brazilian Cohort. Results of the BELIEF Study. Arq Bras Cardiol 2008; 90(3):182-190

    1. Role: protocol development, site selection and author
    2. Early access program
    3. Status: published

Study: Cost Analysis of the Treatment of Acute Decompensated Heart Failure. Levosimendan versus Dobutamine. Arquivos Brasileiros de Cardiologia – Volume 85, Nº 1, Julho 2005.

      1. Role: protocol development, site selection and author
      2. Ph4, HEOR study used for reimbursement application
      3. Status: published

Study: Levosimendan vs. dobutamine: outcomes for acute heart failure patients on b-blockers in SURVIVE. European Journal of Heart Failure (2009) 11, 304–311

    1. Role: Internal Steering Committee, protocol discussions

Study: Randomized Evaluation of Levosimendan Infusion Efficacy in patients with decompensated heart Failure (RELIEF-1).

    1. Role: protocol development, feasibility, site selection
    2. Ph2B study
    3. Status: cancelled due to lack of funding